CO6251290A2 - Nuevas formas cristalinas de 3-(2r-tetrahidrofuril-metil)-2-tioxantina - Google Patents

Nuevas formas cristalinas de 3-(2r-tetrahidrofuril-metil)-2-tioxantina

Info

Publication number
CO6251290A2
CO6251290A2 CO09140840A CO09140840A CO6251290A2 CO 6251290 A2 CO6251290 A2 CO 6251290A2 CO 09140840 A CO09140840 A CO 09140840A CO 09140840 A CO09140840 A CO 09140840A CO 6251290 A2 CO6251290 A2 CO 6251290A2
Authority
CO
Colombia
Prior art keywords
methyl
tetrahydrofuryl
thioxanthin
2theta
powder samples
Prior art date
Application number
CO09140840A
Other languages
English (en)
Inventor
Ricaurte Alicia Lloreda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39744966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6251290(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6251290A2 publication Critical patent/CO6251290A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)

Abstract

1.- La Forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina.2.- La Forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina, caracterizada por proporcionar un patrón dedifracción de rayos X de muestras en polvo que exhibesustancialmente los siguientes valores de d:3.- La forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina, caracterizada por valores °2theta de difracciónde rayos X de muestras en polvo de 23.16 °2theta.4.- La forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina según la reivindicación 3, caracterizada porvalores °2theta de difracción de rayos X de muestras enpolvo de 23.16, 24.46 y 26.80 °2theta.5.- La forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina según la reivindicación 3, caracterizada porvalores °2theta de difracción de rayos X de muestras enpolvo de 18.61, 19.87, 23.16, 24.46 y 26.80 °2theta.6.- Un proceso para la preparación de la forma Ade 3-(2R-tetrahidrofuril-metil)-2-tioxantina según cualquierade las reivindicaciones 1 a 5, que comprende los pasos de:a) Disolver o suspender cualquier forma de 3-(2Rtetrahidrofuril-metil)-2-tioxantina, o una mezcla de cualquierforma en un solvente apropiado;b) permitir a la solución cristalizar;c) aislar la 3-(2R-tetrahidrofuril-metil)-2-tioxantina asíobtenida.7.- La forma B de 3-(2R-tetrahidrofuril-metil)-2-tioxantina.
CO09140840A 2007-06-13 2009-12-09 Nuevas formas cristalinas de 3-(2r-tetrahidrofuril-metil)-2-tioxantina CO6251290A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94367107P 2007-06-13 2007-06-13

Publications (1)

Publication Number Publication Date
CO6251290A2 true CO6251290A2 (es) 2011-02-21

Family

ID=39744966

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09140840A CO6251290A2 (es) 2007-06-13 2009-12-09 Nuevas formas cristalinas de 3-(2r-tetrahidrofuril-metil)-2-tioxantina

Country Status (19)

Country Link
US (1) US20080312311A1 (es)
EP (1) EP2158202A1 (es)
JP (1) JP2010529185A (es)
KR (1) KR20100020002A (es)
CN (1) CN101679435A (es)
AR (1) AR066936A1 (es)
AU (1) AU2008263582A1 (es)
BR (1) BRPI0812480A2 (es)
CA (1) CA2690468A1 (es)
CL (1) CL2008001766A1 (es)
CO (1) CO6251290A2 (es)
EC (1) ECSP109874A (es)
IL (1) IL202281A0 (es)
MX (1) MX2009013126A (es)
PE (1) PE20090367A1 (es)
RU (1) RU2010100484A (es)
TW (1) TW200916096A (es)
UY (1) UY31139A1 (es)
WO (1) WO2008152420A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2010068171A1 (en) * 2008-12-12 2010-06-17 Astrazeneca Ab A process for the preparation of 3- [ (2r) tetrahydrofuran-2- ylmethyl] -2-thioxo-l, 2, 3, 7-tetrahydro-6h-purin-6-one
CN110891572B (zh) * 2017-07-17 2023-08-15 阿斯利康(瑞典)有限公司 用于医学的mpo抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
JP2009533426A (ja) * 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ チオキサンチン誘導体およびそれらのｍｐｏ阻害剤としての用途

Also Published As

Publication number Publication date
AR066936A1 (es) 2009-09-23
TW200916096A (en) 2009-04-16
BRPI0812480A2 (pt) 2017-05-23
EP2158202A1 (en) 2010-03-03
JP2010529185A (ja) 2010-08-26
KR20100020002A (ko) 2010-02-19
AU2008263582A1 (en) 2008-12-18
PE20090367A1 (es) 2009-04-15
MX2009013126A (es) 2010-01-15
WO2008152420A1 (en) 2008-12-18
US20080312311A1 (en) 2008-12-18
ECSP109874A (es) 2010-02-26
IL202281A0 (en) 2010-06-16
CN101679435A (zh) 2010-03-24
UY31139A1 (es) 2009-01-30
CL2008001766A1 (es) 2008-12-19
CA2690468A1 (en) 2008-12-18
RU2010100484A (ru) 2011-07-20

Similar Documents

Publication Publication Date Title
CL2020000030A1 (es) Aparatos y métodos de cribas moldeadas por inyección. (divisional solicitud 201801786).
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CO6251290A2 (es) Nuevas formas cristalinas de 3-(2r-tetrahidrofuril-metil)-2-tioxantina
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2008002542A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar los mismos ref. 01142.0379-00267 (am101946sv)
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY34111A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY31698A (es) Preparacion solida de desintegracion oral
ES2644438T3 (es) Aparato para generar energía mediante gasificación
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
GT200600347A (es) Nueva formula cristalina iii de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
BR112017009937A2 (pt) moléculas tendo utilidade pesticida, e intermediários, composições, e processos, relacionados com elas
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CR20150456A (es) Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen
BR112015018478B8 (pt) Uso de um ou mais ésteres, uso do solvente, uso de ésteres derivados de dioxolano, composição de revestimento, e, sistema ligante para fundição
BR112015025457A2 (pt) método de fabricação de um cátodo
WO2016025774A8 (en) Microlattice structures including flame retardant materials and compositions and methods for forming the same
DK1951738T3 (da) Nye krystallinske former af rostafuroxin

Legal Events

Date Code Title Description
FA Application withdrawn